title: Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.
abstract: Small animals were immunized with plasmid DNA encoding HIV-1 envelope gp120 either intramuscularly by needle injection (mice and guinea pigs) or epidermally with the Accell gene gun (guinea pits). Subsequently, the animals were boosted with a recombinant gp120 protein subunit vaccine in an oil-in-water based adjuvant, MF59. Antibodies and cytotoxic T-lymphocyte (CTL) immune responses to the HIV envelope glycoprotein were observed in animals immunized with gp120 DNA derived from the HIV-1SF2 laboratory strain or from HIV-1 field isolates. Titers of ELISA antibodies and serum neutralizing antibodies against the HIV-1SF2 laboratory isolate were substantially increased in DNA-immunized animals following a single boost with recombinant gp120 protein subunit. This DNA prime/protein subunit boost immunization approach may be important for vaccination against infectious agents such as HIV for which it is difficult to raise strong antiviral humoral responses with DNA vaccination alone.
authors.affiliation: Geniva Inc. Middleton, WI 53562, USA.
authors.forename: S W
authors.initials: SW
authors.lastname: Barnett
authors.forename: S
authors.initials: S
authors.lastname: Rajasekar
authors.forename: H
authors.initials: H
authors.lastname: Legg
authors.forename: B
authors.initials: B
authors.lastname: Doe
authors.forename: D H
authors.initials: DH
authors.lastname: Fuller
authors.forename: J R
authors.initials: JR
authors.lastname: Haynes
authors.forename: C M
authors.initials: CM
authors.lastname: Walker
authors.forename: K S
authors.initials: KS
authors.lastname: Steimer
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control; D000276:Adjuvants, Immunologic; D000818:Animals; D019470:Biolistics; D004279:DNA, Viral / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D006168:Guinea Pigs; D015483:HIV Antibodies / Q000096:biosynthesis*; D015699:HIV Envelope Protein gp120 / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D007273:Injections, Intramuscular; D051379:Mice; D008807:Mice, Inbred BALB C; D010957:Plasmids / Q000235:genetics; D011136:Polysorbates / Q000032:analysis; D013185:Squalene / Q000032:analysis / Q000276:immunology; D013501:Surface-Active Agents; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D004279:DNA, Viral; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C089950:MF59 oil emulsion; D011136:Polysorbates; D013501:Surface-Active Agents; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D013185:Squalene